FoxP3+ and IL-17+ cells are correlated with improved prognosis in cervical adenocarcinoma

Cancer Immunology, Immunotherapy

Volumn 64, Issue 6, 2015, Pages 745-753

  Punt, Simone ^a   van Vliet, Marjolein E ^a   Spaans, Vivian M ^a   de Kroon, Cornelis D ^a   Fleuren, Gert Jan ^a   Gorter, Arko ^a   Jordanova, Ekaterina S ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; IL 17; Th17; Treg; Tumor microenvironment; Uterine cervical cancer

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PARAFFIN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TUMOR INVASION; TUMOR VOLUME; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; DISEASE COURSE; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PROGNOSIS; T LYMPHOCYTE; TISSUE FIXATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-17; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; PARAFFIN EMBEDDING; PROGNOSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TISSUE FIXATION; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS;

EID: 84930418514     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1678-4     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30. doi:10.3322/caac.21166
2. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S (2004) Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 100:1035–1044. doi:10.1002/cncr.20064
3. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH (2010) Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer 102:1692–1698. doi:10.1038/sj.bjc.6605705
4. Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS et al (2012) Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 125:287–291. doi:10.1016/j.ygyno.2012.01.012
5. Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH et al (2011) A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol 120:439–443. doi:10.1016/j.ygyno.2010.11.022
6. Eifel PJ, Burke TW, Morris M, Smith TL (1995) Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59:38–44. doi:10.1006/gyno.1995.1265
7. Shimada M, Nishimura R, Nogawa T, Hatae M, Takehara K, Yamada H et al (2013) Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance. Mol Clin Oncol 1:780–784. doi:10.3892/mco.2013.112
8. Hopkins MP, Morley GW (1991) A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 77:912–917
9. Shingleton HM, Bell MC, Fremgen A, Chmiel JS, Russell AH, Jones WB et al (1995) Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer 76:1948–1955. doi:10.1002/1097-0142(19951115)76:10+<1948::AID-CNCR2820761311>3.0.CO;2-T
10. Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S (2012) Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol 125:292–296. doi:10.1016/j.ygyno.2012.01.034
11. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ (2005) Cervical cancer in the Netherlands 1989–1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 113:1005–1009. doi:10.1002/ijc.20678
12. Sherman ME, Wang SS, Carreon J, Devesa SS (2005) Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 103:1258–1264. doi:10.1002/cncr.20877
13. Gien LT, Beauchemin MC, Thomas G (2010) Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 116:140–146. doi:10.1016/j.ygyno.2009.09.040
14. Rose PG (2012) Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm? Gynecol Oncol 125:285–286. doi:10.1016/j.ygyno.2012.03.010
15. Contag SA, Gostout BS, Clayton AC, Dixon MH, McGovern RM, Calhoun ES (2004) Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol 95:610–617. doi:10.1016/j.ygyno.2004.08.021
16. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12:AID-PATH431>3.0.CO;2-F
17. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423–428. doi:10.1056/NEJM199802123380703
18. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545. doi:10.1016/S0140-6736(00)04046-0
19. Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N et al (2012) Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol 127:412–419. doi:10.1016/j.ygyno.2012.07.098
20. Bettelli E, Korn T, Kuchroo VK (2007) Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 19:652–657. doi:10.1016/j.coi.2007.07.020
21. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. Nature 453:1051–1057. doi:10.1038/nature07036
22. Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182:10–20. doi:10.1016/j.ajpath.2012.08.041
23. Adurthi S, Mukherjee G, Krishnamurthy H, Sudhir K, Bafna UD, Umadevi K et al (2012) Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells. Int J Gynecol Cancer 22:1130–1137. doi:10.1097/IGC.0b013e318262aa53
24. Santin AD, Hermonat PL, Hiserodt JC, Fruehauf J, Schranz V, Barclay D et al (1997) Differential transforming growth factor-beta secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 64:477–480. doi:10.1006/gyno.1996.4579
25. +/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 14:2028–2035. doi:10.1158/1078-0432.CCR-07-4554
26. Punt S, Fleuren GJ, Kritikou E, Lubberts E, Trimbos JB, Jordanova ES et al (2015) Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. OncoImmunology 4:e984539. doi:10.4161/2162402X.2014.984539
27. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES (2012) HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med 10:184. doi:10.1186/1479-5876-10-184
28. Wilbur DC, Mikami Y, Colgan TJ, Park KJ, Ferenczy AS, Ronnett BM et al (2014) Tumours of the uterine cervix. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) WHO classification of tumours of female reproductive organs, 4th edn. IARC, Lyon, pp 183–189
29. Shah W, Yan X, Jing L, Zhou Y, Chen H, Wang Y (2011) A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 8:59–66. doi:10.1038/cmi.2010.56
30. + regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. doi:10.1007/s00262-014-1651-7
31. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS et al (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586–2593. doi:10.1200/JCO.2006.09.4565
32. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.1038/nm1093
33. Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P et al (2008) Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 44:1875–1882. doi:10.1016/j.ejca.2008.05.017
34. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465–472. doi:10.1158/1078-0432.CCR-05-1886
35. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S et al (2012) Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 77:918–925. doi:10.1111/j.1365-2265.2012.04482.x
36. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186–192. doi:10.1200/JCO.2008.18.7229
37. + regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60:909–918. doi:10.1007/s00262-011-1046-y
38. Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22:327–334. doi:10.1016/j.semcancer.2012.03.004
39. Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES (2015) The correlations between IL-17 versus Th17 cells and cancer patient survival: a systematic review. OncoImmunology 4:e984547. doi:10.4161/2162402X.2014.984547
40. Ji Y, Zhang W (2010) Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 59:979–987. doi:10.1007/s00262-010-0849-6
41. Zijlmans HJ, Punt S, Fleuren GJ, Trimbos JB, Kenter GG, Gorter A (2012) Role of IL-12p40 in cervical carcinoma. Br J Cancer 107:1956–1962. doi:10.1038/bjc.2012.488
42. Chen JG, Xia JC, Liang XT, Pan K, Wang W, Lv L et al (2011) Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int J Biol Sci 7:53–60. doi:10.7150/ijbs.7.53
43. Yan J, Liu XL, Xiao G, Li NL, Deng YN, Han LZ et al (2014) Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma. PLoS ONE 9:e96080. doi:10.1371/journal.pone.0096080
44. Tornesello ML, Buonaguro L, Buonaguro FM (2013) Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol 128:442–448. doi:10.1016/j.ygyno.2012.11.017
45. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van HP et al (2013) Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119:3776–3783. doi:10.1002/cncr.28288
46. Schrevel M, Karim R, ter Haar NT, van der Burg SH, Trimbos JB, Fleuren GJ et al (2012) CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br J Cancer 106:1520–1525. doi:10.1038/bjc.2012.110